Ziekenhuisgroep Twente, locatie Almelo
Welcome,         Profile    Billing    Logout  
 9 Trials 
59 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kümmel, Sherko
ADAPTlate, NCT04565054 / 2019-001488-60: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Recruiting
3
1260
Europe
Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios
West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.
Breast Cancer Female
08/26
03/28
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Active, not recruiting
3
1684
Europe
Ribociclib 200Mg Oral Tablet, Kisqali
West German Study Group, Novartis, Genomic Health®, Inc.
Breast Cancer Female
07/27
07/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
PHERGAIN-2, NCT04733118 / 2020-003205-66: Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

Active, not recruiting
2
393
Europe
Trastuzumab and Pertuzumab (FDC SC) and T-DM1, Trastuzumab emtansine, Phesgo, Kadcyla
MedSIR, Hoffmann-La Roche
Early Breast Cancer
09/25
03/28
GeparPiPPa, NCT05306041: Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

Recruiting
2
170
Europe
Inavolisib, PHESGO, Endocrine therapy
German Breast Group, Roche Pharma AG
HER2-positive Breast Cancer
10/26
01/27
ADAPT-TN-III, NCT06081244: NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC

Recruiting
2
348
Europe
Sacituzumab govitecan, Trodelvy, Pembrolizumab, Keytruda
West German Study Group, Gilead Sciences, Merck Sharp & Dohme LLC
Triple Negative Breast Cancer
09/29
09/29
NCT06638307: A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Recruiting
1
124
US
MEN2312, Elacestrant, Orserdu
Stemline Therapeutics, Inc.
Advanced Breast Cancer
10/25
10/26
CRANIO4US, NCT04319510: Supportive Effects of Craniosacral Therapy for Female Patients With Breast Cancer and Their Partners

Active, not recruiting
N/A
102
Europe
Craniosacral therapy, Craniosacral self-help group training, Treatment as usal / wait list
Universität Duisburg-Essen
Breast Cancer, Complementary Therapies
07/25
12/25
NCT03463954: Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors

Recruiting
N/A
122
Europe, US
Novilase Laser ablation
Novian Health Inc.
Malignant Neoplasm of Breast
09/25
09/25
TAXIS, NCT03513614: Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer

Recruiting
N/A
1500
Europe, Canada, US, RoW
Tailored axillary surgery - both Arms, Radiotherapy - Arm A, Radiotherapy - Arm B
University Hospital, Basel, Switzerland, ETOP IBCSG Partners Foundation, Austrian Breast Cancer Study Group
Node-positive Breast Cancer
12/29
12/36
OPBC-02PREPEC, NCT04293146: Pre- Versus Sub-pectoral Implant-based Breast Reconstruction After Skin-sparing Mastectomy or Nipple-sparing Mastectomy

Active, not recruiting
N/A
382
Europe, US
pre-pectoral IBBR, sub-pectoral IBBR
University Hospital, Basel, Switzerland, Swiss National Science Foundation
Breast Reconstruction, Implant-Based Breast Reconstruction (IBBR)
05/25
02/33
Thill, Marc
PADMA, NCT03355157 / 2016-004482-89: A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - Study).

Completed
4
130
Europe
Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)
German Breast Group, Pfizer, AMS Advanced Medical Services GmbH
Metastatic Breast Cancer
08/24
08/24
CAPTOR-BC, NCT05452213: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

Recruiting
4
1000
Europe
Ribociclib
Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals
Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer
10/24
10/26
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
SASCIA, NCT04595565 / 2019-004100-35: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting
3
1332
Europe
Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy
German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER
HER2-negative Breast Cancer, Triple Negative Breast Cancer
03/27
03/29
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Active, not recruiting
3
1684
Europe
Ribociclib 200Mg Oral Tablet, Kisqali
West German Study Group, Novartis, Genomic Health®, Inc.
Breast Cancer Female
07/27
07/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
ELEMENT, NCT06201234: Evaluating the Addition of Elacestrant (oral SERD) to Olaparib (PARP-inhibitor) in Patients with Advanced/metastatic HR+/HER2- Breast Cancer

Recruiting
2
176
Europe
Olaparib + Elacestrant, Olaparib
German Breast Group, Stemline Therapeutics, Inc.
Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced or Metastatic Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
12/28
12/28
ADAPTHER2-IV, NCT05704829: NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer

Recruiting
2
402
Europe
Trastuzumab deruxtecan, ENHERTU, Standard-of-Care, Chemotherapy+T+P
West German Study Group, AstraZeneca
HER2-positive Early Breast Cancer
06/26
06/28
ADAPT-TN-III, NCT06081244: NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC

Recruiting
2
348
Europe
Sacituzumab govitecan, Trodelvy, Pembrolizumab, Keytruda
West German Study Group, Gilead Sciences, Merck Sharp & Dohme LLC
Triple Negative Breast Cancer
09/29
09/29
PULSE, NCT03975855: Evaluation of NeoNavia® Biopsy System in Axillary Lymph Nodes

Completed
N/A
140
Europe
NeoNavia® Biopsy System
NeoDynamics AB
Breast Cancer
06/21
04/23
NCT05142787: Magseed Pro(R)/ Sentimag(R) Gen3

Recruiting
N/A
224
Europe
Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics
Endomagnetics Ltd.
Breast Cancer
12/25
06/26
NCT05458739: The ClearCoast™ Magnetic Resonance Outcome PMS Study

Completed
N/A
93
Europe
ClearCoast MR System
Clear Cut Medical Ltd.
Breast Cancer
07/24
08/24
VISION I, NCT04289935: Intelligent Vacuum Assisted Biopsy Immediately Before Surgery As an Intra- or Pre-Operative Surrogate for Patient Response to Neoadjuvant Chemotherapy for Breast Cancer

Recruiting
N/A
420
Europe, RoW
Vacuum assisted biopsy (VAB)
Klinik Hirslanden, Zurich, Oncoplastic Breast Consortium (OPBC)
Breast Cancer
06/25
06/25
GENERATE, NCT05867927: - Next GENERATion of GynEcological Surgery - Robotic Assisted Surgery in Gynecological Indications

Recruiting
N/A
1125
Europe
Robotic-assisted surgery (da Vinci), Non-da Vinci Surgery
Intuitive Surgical
GYN Disorders
09/27
12/27
Wirtz, Marina
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
ADAPTlate, NCT04565054 / 2019-001488-60: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Recruiting
3
1260
Europe
Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios
West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.
Breast Cancer Female
08/26
03/28
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Hackmann, John
ADAPTlate, NCT04565054 / 2019-001488-60: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Recruiting
3
1260
Europe
Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios
West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.
Breast Cancer Female
08/26
03/28
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Active, not recruiting
3
1684
Europe
Ribociclib 200Mg Oral Tablet, Kisqali
West German Study Group, Novartis, Genomic Health®, Inc.
Breast Cancer Female
07/27
07/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
ADAPT-TN-III, NCT06081244: NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC

Recruiting
2
348
Europe
Sacituzumab govitecan, Trodelvy, Pembrolizumab, Keytruda
West German Study Group, Gilead Sciences, Merck Sharp & Dohme LLC
Triple Negative Breast Cancer
09/29
09/29
MOREAU, Lionel
PROMETHEE, NCT06646471: PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies

Recruiting
4
500
Europe
Bio-bank repository, Quality of Life (QoL), G-Code
Groupe Francais De Pneumo-Cancerologie
Non Small Cell Lung Cancer, Lung Cancer
08/26
08/28
ELDERLY, NCT03977194: Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy

Active, not recruiting
3
500
Europe
Carboplatin, Paclitaxel, Atezolizumab
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
08/24
12/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
DIAL, NCT05255302 / 2021-006044-27: De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

Recruiting
2/3
1360
Europe
Pembrolizumab before randomization, Chemotherapy, Pemetrexed, Pembrolizumab after randomization
Intergroupe Francophone de Cancerologie Thoracique, IFCT
Metastatic NSCLC
05/25
06/29
ORBITAL, NCT04233021: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation

Completed
2
57
Europe
Osimertinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation
03/23
12/24
SAVIMMUNE, NCT04108026 / 2018-004742-42: Immunotherapy in Patient with Poor General Condition

Active, not recruiting
2
50
Europe
Durvalumab
Intergroupe Francophone de Cancerologie Thoracique, IFCT, AstraZeneca
Non-small Cell Lung Cancer Stage IV
11/23
10/25
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

Completed
2
23
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
08/22
12/24
ENCO-BRAF, NCT04526782 / 2019-004621-24: ENCOrafenib With Binimetinib in bRAF NSCLC

Hourglass Jul 2022 - Dec 2022 : Pivotal data readout from ENCO-BRAF trial in combination with Mektovi for NSCLC
Active, not recruiting
2
119
Europe
Encorafenib 75 MG, Binimetinib 15 MG
Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre
Non Small Cell Lung Cancer, BRAF V600E
06/25
03/26
REPOROS, NCT06552234: Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

Not yet recruiting
2
30
Europe
Repotrectinib
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Groupe Français de Pneumo-Cancérologie, Hospices Civils de Lyon
NSCLC Stage IV, NSCLC, Stage III
09/31
09/31
NCT04621188: Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS)

Active, not recruiting
2
54
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
02/25
02/27
ADAPTABLE, NCT05781308: Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy

Active, not recruiting
2
156
Europe
Paclitaxel, Bevacizumab, Avastin, Atezolizumab, Tecentriq
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer
09/25
06/26
TAXIO, NCT05856695: Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)

Recruiting
2
67
Europe
Carboplatin + Paclitaxel + Durvalumab
Intergroupe Francophone de Cancerologie Thoracique
Small Cell Lung Cancer Extensive Stage
02/26
02/28
SAFIR 03, NCT05625087: Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

Recruiting
2
162
Europe
Alpelisib, Fulvestrant, Ribociclib
UNICANCER, Novartis, Breast Cancer Research Foundation
Breast Cancer Stage IV
07/28
06/30
ETNA, NCT06078384: Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

Recruiting
2
354
Europe
Pembrolizumab 25 mg/ml, keytruda, Paclitaxel injection, Taxol
UNICANCER, MSD France, SOLTI Breast Cancer Research Group, Gustave Roussy, Cancer Campus, Grand Paris, Vall Hebron Insitut Recerca
Triple-negative Breast Cancer
01/32
01/32
NCT04720339: Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy.

Recruiting
N/A
250
Europe
Molecular monitoring by quantification of cell-free DNA
University Hospital, Strasbourg, France
NSCLC, IMMUNOTHERAPY, QUANTIFICATION OF CELL-FREE DNA
05/25
10/27
ROSIE, NCT06053099: A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

Recruiting
N/A
300
Europe
Plasma ctDNA, FFPE blocks
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19, EGFR L858R
10/31
10/31
Stahl, Nicole
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
GENERATE, NCT05867927: - Next GENERATion of GynEcological Surgery - Robotic Assisted Surgery in Gynecological Indications

Recruiting
N/A
1125
Europe
Robotic-assisted surgery (da Vinci), Non-da Vinci Surgery
Intuitive Surgical
GYN Disorders
09/27
12/27
NCT04101851: Omission of SLNB in Triple-negative and HER2-positive Breast Cancer Patients with RCR and PCR in the Breast After NAST

Active, not recruiting
N/A
350
Europe
omission of SLNB
Toralf Reimer, MD PhD, European Breast Cancer Reseach Association of Surgical Trialists, University Medicine Rostock, Rostock, Germany (sponsor), Else Kröner-Fresenius-Stiftung (funding), German Society of Senology (funding)
Breast Cancer Female, Breast Cancer
01/28
01/28
BAILLEUX, Caroline
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
InTTercePT, NCT05041842 / 2020-005735-79: Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer

Active, not recruiting
2
53
Europe
Tucatinib, Pertuzumab, Perjeta®, Trastuzumab, Herceptin® or Biosimilar, Hormone therapy, Pertuzumab/ Trastuzumab, Phesgo®
UNICANCER, Seagen Inc., ARCAGY/ GINECO GROUP
Metastatic Breast Cancer With a Isolated Brain Progression
04/25
04/26
ETIC-LM, NCT05800275: Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients with Leptomeningeal Disease

Recruiting
2
30
NA
Tucatinib Oral Tablet, Capecitabine tablets, Trastuzumab Injection
UNICANCER, Seagen Inc.
Leptomeningeal Metastasis, Leptomeningeal Disease, HER2-positive Metastatic Breast Cancer
12/26
06/27
SAFIR 03, NCT05625087: Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

Recruiting
2
162
Europe
Alpelisib, Fulvestrant, Ribociclib
UNICANCER, Novartis, Breast Cancer Research Foundation
Breast Cancer Stage IV
07/28
06/30
CALHYS, NCT05664893: Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient

Recruiting
1/2
85
Europe
Ribociclib Oral Tablet
Centre Antoine Lacassagne
HER2 Negative Breast Cancer Not Immediately Operated
10/31
03/33
ARIANE, NCT06400849: Comparison of the Efficacy of Cryotherapy Combined With Compression in Preventing Neuropathy

Recruiting
N/A
60
Europe
cryotherapy alone of the upper or lower limbs, cryotherapy and crompression of the upper or lower limbs
Centre Antoine Lacassagne, Thuasne
Non-metastatic Breast Cancer
12/26
06/27
Siemerink, Ester
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kümmel, Sherko
ADAPTlate, NCT04565054 / 2019-001488-60: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Recruiting
3
1260
Europe
Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios
West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.
Breast Cancer Female
08/26
03/28
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Active, not recruiting
3
1684
Europe
Ribociclib 200Mg Oral Tablet, Kisqali
West German Study Group, Novartis, Genomic Health®, Inc.
Breast Cancer Female
07/27
07/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
PHERGAIN-2, NCT04733118 / 2020-003205-66: Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer

Active, not recruiting
2
393
Europe
Trastuzumab and Pertuzumab (FDC SC) and T-DM1, Trastuzumab emtansine, Phesgo, Kadcyla
MedSIR, Hoffmann-La Roche
Early Breast Cancer
09/25
03/28
GeparPiPPa, NCT05306041: Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

Recruiting
2
170
Europe
Inavolisib, PHESGO, Endocrine therapy
German Breast Group, Roche Pharma AG
HER2-positive Breast Cancer
10/26
01/27
ADAPT-TN-III, NCT06081244: NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC

Recruiting
2
348
Europe
Sacituzumab govitecan, Trodelvy, Pembrolizumab, Keytruda
West German Study Group, Gilead Sciences, Merck Sharp & Dohme LLC
Triple Negative Breast Cancer
09/29
09/29
NCT06638307: A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Recruiting
1
124
US
MEN2312, Elacestrant, Orserdu
Stemline Therapeutics, Inc.
Advanced Breast Cancer
10/25
10/26
CRANIO4US, NCT04319510: Supportive Effects of Craniosacral Therapy for Female Patients With Breast Cancer and Their Partners

Active, not recruiting
N/A
102
Europe
Craniosacral therapy, Craniosacral self-help group training, Treatment as usal / wait list
Universität Duisburg-Essen
Breast Cancer, Complementary Therapies
07/25
12/25
NCT03463954: Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors

Recruiting
N/A
122
Europe, US
Novilase Laser ablation
Novian Health Inc.
Malignant Neoplasm of Breast
09/25
09/25
TAXIS, NCT03513614: Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer

Recruiting
N/A
1500
Europe, Canada, US, RoW
Tailored axillary surgery - both Arms, Radiotherapy - Arm A, Radiotherapy - Arm B
University Hospital, Basel, Switzerland, ETOP IBCSG Partners Foundation, Austrian Breast Cancer Study Group
Node-positive Breast Cancer
12/29
12/36
OPBC-02PREPEC, NCT04293146: Pre- Versus Sub-pectoral Implant-based Breast Reconstruction After Skin-sparing Mastectomy or Nipple-sparing Mastectomy

Active, not recruiting
N/A
382
Europe, US
pre-pectoral IBBR, sub-pectoral IBBR
University Hospital, Basel, Switzerland, Swiss National Science Foundation
Breast Reconstruction, Implant-Based Breast Reconstruction (IBBR)
05/25
02/33
Thill, Marc
PADMA, NCT03355157 / 2016-004482-89: A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - Study).

Completed
4
130
Europe
Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)
German Breast Group, Pfizer, AMS Advanced Medical Services GmbH
Metastatic Breast Cancer
08/24
08/24
CAPTOR-BC, NCT05452213: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

Recruiting
4
1000
Europe
Ribociclib
Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals
Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer
10/24
10/26
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
SASCIA, NCT04595565 / 2019-004100-35: Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Active, not recruiting
3
1332
Europe
Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy
German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER
HER2-negative Breast Cancer, Triple Negative Breast Cancer
03/27
03/29
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Active, not recruiting
3
1684
Europe
Ribociclib 200Mg Oral Tablet, Kisqali
West German Study Group, Novartis, Genomic Health®, Inc.
Breast Cancer Female
07/27
07/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

Recruiting
3
270
Europe, Canada, US, RoW
avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex
Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group
Low Grade Serous Ovarian Cancer
10/28
02/31
ELEMENT, NCT06201234: Evaluating the Addition of Elacestrant (oral SERD) to Olaparib (PARP-inhibitor) in Patients with Advanced/metastatic HR+/HER2- Breast Cancer

Recruiting
2
176
Europe
Olaparib + Elacestrant, Olaparib
German Breast Group, Stemline Therapeutics, Inc.
Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced or Metastatic Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
12/28
12/28
ADAPTHER2-IV, NCT05704829: NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer

Recruiting
2
402
Europe
Trastuzumab deruxtecan, ENHERTU, Standard-of-Care, Chemotherapy+T+P
West German Study Group, AstraZeneca
HER2-positive Early Breast Cancer
06/26
06/28
ADAPT-TN-III, NCT06081244: NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC

Recruiting
2
348
Europe
Sacituzumab govitecan, Trodelvy, Pembrolizumab, Keytruda
West German Study Group, Gilead Sciences, Merck Sharp & Dohme LLC
Triple Negative Breast Cancer
09/29
09/29
PULSE, NCT03975855: Evaluation of NeoNavia® Biopsy System in Axillary Lymph Nodes

Completed
N/A
140
Europe
NeoNavia® Biopsy System
NeoDynamics AB
Breast Cancer
06/21
04/23
NCT05142787: Magseed Pro(R)/ Sentimag(R) Gen3

Recruiting
N/A
224
Europe
Magseed Pro(R) and Sentimag(R) Gen3 by Endomagnetics
Endomagnetics Ltd.
Breast Cancer
12/25
06/26
NCT05458739: The ClearCoast™ Magnetic Resonance Outcome PMS Study

Completed
N/A
93
Europe
ClearCoast MR System
Clear Cut Medical Ltd.
Breast Cancer
07/24
08/24
VISION I, NCT04289935: Intelligent Vacuum Assisted Biopsy Immediately Before Surgery As an Intra- or Pre-Operative Surrogate for Patient Response to Neoadjuvant Chemotherapy for Breast Cancer

Recruiting
N/A
420
Europe, RoW
Vacuum assisted biopsy (VAB)
Klinik Hirslanden, Zurich, Oncoplastic Breast Consortium (OPBC)
Breast Cancer
06/25
06/25
GENERATE, NCT05867927: - Next GENERATion of GynEcological Surgery - Robotic Assisted Surgery in Gynecological Indications

Recruiting
N/A
1125
Europe
Robotic-assisted surgery (da Vinci), Non-da Vinci Surgery
Intuitive Surgical
GYN Disorders
09/27
12/27
Wirtz, Marina
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
ADAPTlate, NCT04565054 / 2019-001488-60: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Recruiting
3
1260
Europe
Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios
West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.
Breast Cancer Female
08/26
03/28
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Hackmann, John
ADAPTlate, NCT04565054 / 2019-001488-60: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Recruiting
3
1260
Europe
Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios
West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.
Breast Cancer Female
08/26
03/28
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Active, not recruiting
3
1684
Europe
Ribociclib 200Mg Oral Tablet, Kisqali
West German Study Group, Novartis, Genomic Health®, Inc.
Breast Cancer Female
07/27
07/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
ADAPT-TN-III, NCT06081244: NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC

Recruiting
2
348
Europe
Sacituzumab govitecan, Trodelvy, Pembrolizumab, Keytruda
West German Study Group, Gilead Sciences, Merck Sharp & Dohme LLC
Triple Negative Breast Cancer
09/29
09/29
MOREAU, Lionel
PROMETHEE, NCT06646471: PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With Thoracic Malignancies

Recruiting
4
500
Europe
Bio-bank repository, Quality of Life (QoL), G-Code
Groupe Francais De Pneumo-Cancerologie
Non Small Cell Lung Cancer, Lung Cancer
08/26
08/28
ELDERLY, NCT03977194: Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy

Active, not recruiting
3
500
Europe
Carboplatin, Paclitaxel, Atezolizumab
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
08/24
12/26
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
DIAL, NCT05255302 / 2021-006044-27: De-escalation Immunotherapy mAintenance Duration Trial for Stage IV Lung Cancer Patients With Disease Control After Chemo-immunotherapy Induction

Recruiting
2/3
1360
Europe
Pembrolizumab before randomization, Chemotherapy, Pemetrexed, Pembrolizumab after randomization
Intergroupe Francophone de Cancerologie Thoracique, IFCT
Metastatic NSCLC
05/25
06/29
ORBITAL, NCT04233021: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation

Completed
2
57
Europe
Osimertinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation
03/23
12/24
SAVIMMUNE, NCT04108026 / 2018-004742-42: Immunotherapy in Patient with Poor General Condition

Active, not recruiting
2
50
Europe
Durvalumab
Intergroupe Francophone de Cancerologie Thoracique, IFCT, AstraZeneca
Non-small Cell Lung Cancer Stage IV
11/23
10/25
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

Completed
2
23
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
08/22
12/24
ENCO-BRAF, NCT04526782 / 2019-004621-24: ENCOrafenib With Binimetinib in bRAF NSCLC

Hourglass Jul 2022 - Dec 2022 : Pivotal data readout from ENCO-BRAF trial in combination with Mektovi for NSCLC
Active, not recruiting
2
119
Europe
Encorafenib 75 MG, Binimetinib 15 MG
Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre
Non Small Cell Lung Cancer, BRAF V600E
06/25
03/26
REPOROS, NCT06552234: Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

Not yet recruiting
2
30
Europe
Repotrectinib
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer, Groupe Français de Pneumo-Cancérologie, Hospices Civils de Lyon
NSCLC Stage IV, NSCLC, Stage III
09/31
09/31
NCT04621188: Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS)

Active, not recruiting
2
54
Europe
Lorlatinib
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer Metastatic
02/25
02/27
ADAPTABLE, NCT05781308: Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy

Active, not recruiting
2
156
Europe
Paclitaxel, Bevacizumab, Avastin, Atezolizumab, Tecentriq
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer
09/25
06/26
TAXIO, NCT05856695: Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)

Recruiting
2
67
Europe
Carboplatin + Paclitaxel + Durvalumab
Intergroupe Francophone de Cancerologie Thoracique
Small Cell Lung Cancer Extensive Stage
02/26
02/28
SAFIR 03, NCT05625087: Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

Recruiting
2
162
Europe
Alpelisib, Fulvestrant, Ribociclib
UNICANCER, Novartis, Breast Cancer Research Foundation
Breast Cancer Stage IV
07/28
06/30
ETNA, NCT06078384: Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

Recruiting
2
354
Europe
Pembrolizumab 25 mg/ml, keytruda, Paclitaxel injection, Taxol
UNICANCER, MSD France, SOLTI Breast Cancer Research Group, Gustave Roussy, Cancer Campus, Grand Paris, Vall Hebron Insitut Recerca
Triple-negative Breast Cancer
01/32
01/32
NCT04720339: Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy.

Recruiting
N/A
250
Europe
Molecular monitoring by quantification of cell-free DNA
University Hospital, Strasbourg, France
NSCLC, IMMUNOTHERAPY, QUANTIFICATION OF CELL-FREE DNA
05/25
10/27
ROSIE, NCT06053099: A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)

Recruiting
N/A
300
Europe
Plasma ctDNA, FFPE blocks
Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19, EGFR L858R
10/31
10/31
Stahl, Nicole
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
GENERATE, NCT05867927: - Next GENERATion of GynEcological Surgery - Robotic Assisted Surgery in Gynecological Indications

Recruiting
N/A
1125
Europe
Robotic-assisted surgery (da Vinci), Non-da Vinci Surgery
Intuitive Surgical
GYN Disorders
09/27
12/27
NCT04101851: Omission of SLNB in Triple-negative and HER2-positive Breast Cancer Patients with RCR and PCR in the Breast After NAST

Active, not recruiting
N/A
350
Europe
omission of SLNB
Toralf Reimer, MD PhD, European Breast Cancer Reseach Association of Surgical Trialists, University Medicine Rostock, Rostock, Germany (sponsor), Else Kröner-Fresenius-Stiftung (funding), German Society of Senology (funding)
Breast Cancer Female, Breast Cancer
01/28
01/28
BAILLEUX, Caroline
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
InTTercePT, NCT05041842 / 2020-005735-79: Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer

Active, not recruiting
2
53
Europe
Tucatinib, Pertuzumab, Perjeta®, Trastuzumab, Herceptin® or Biosimilar, Hormone therapy, Pertuzumab/ Trastuzumab, Phesgo®
UNICANCER, Seagen Inc., ARCAGY/ GINECO GROUP
Metastatic Breast Cancer With a Isolated Brain Progression
04/25
04/26
ETIC-LM, NCT05800275: Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients with Leptomeningeal Disease

Recruiting
2
30
NA
Tucatinib Oral Tablet, Capecitabine tablets, Trastuzumab Injection
UNICANCER, Seagen Inc.
Leptomeningeal Metastasis, Leptomeningeal Disease, HER2-positive Metastatic Breast Cancer
12/26
06/27
SAFIR 03, NCT05625087: Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

Recruiting
2
162
Europe
Alpelisib, Fulvestrant, Ribociclib
UNICANCER, Novartis, Breast Cancer Research Foundation
Breast Cancer Stage IV
07/28
06/30
CALHYS, NCT05664893: Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient

Recruiting
1/2
85
Europe
Ribociclib Oral Tablet
Centre Antoine Lacassagne
HER2 Negative Breast Cancer Not Immediately Operated
10/31
03/33
ARIANE, NCT06400849: Comparison of the Efficacy of Cryotherapy Combined With Compression in Preventing Neuropathy

Recruiting
N/A
60
Europe
cryotherapy alone of the upper or lower limbs, cryotherapy and crompression of the upper or lower limbs
Centre Antoine Lacassagne, Thuasne
Non-metastatic Breast Cancer
12/26
06/27
Siemerink, Ester
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
8000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32

Download Options